FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

Phase 1CYWC628Positive

AI Analysis

Summary

FibroBiologics reported Q2 2026 financial results and announced first patient dosing in a phase 1/2 clinical trial evaluating CYWC628 for diabetic foot ulcers, with interim results expected in 2H 2026.

Clinical Trial Data

Phase

1/2

Outcome Details

First patients dosed in phase 1/2 clinical trial

Importance:5/10

Sentiment:

0.50

clinical trialwound carediabetic foot ulcersphase 1/2trial initiation

Related Companies

$FBLG

Read the original article

Published by PR Newswire Biotech on July 31, 2026 9:34 PM

Read Original